Board summary
Key figures
49,671
Registered population
61.1% aged 18–64
13.2%
Aged 65+
ICB 14.9% · England 17.9%
61.6%
In IMD quintile 1
ICB 40.7% · England 21.0%
~29,166
Core20 residents (est.)
Resident basis; registered basis ~31,290 · see page 3
7,109
Hypertension register
+2.91% in 3 yrs · England +5.60%
668
SMI register
21.4% of Rochdale (LAD)'s
1,413
COPD register
Reviews -3.96% in 3 yrs
Forecast to 2030
8,081
Hypertension patients, 2030
+972 on today
75.4%
QRISK ≥20% on statins, 2030
+2.22pp over 3 yrs
3.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review shortfall across the register.
Annual asthma review coverage is 61.5% (England 65.7%), leaving about 1,300 of 3,379 registered patients without a recorded review in 12 months.
Age-five MMR second dose trails first.
At age five, MMR dose 2 coverage is 85.5% against 91.2% for dose 1 (5.7 pp lower) and below the 95.0% target.
SMI blood pressure checks outpace England.
SMI blood pressure recording rose +8.9 pp over 2023 to 2025 (England +4.4 pp), reaching 84.8% against 83.4% in England.
Population, age and ethnicity
A registered 25.7% aged 0–17 contrasts with 863 catchment care home beds
Canalside PCN has 49,671 registered patients across member practices. Children aged 0–17 make up 25.7% (12,765 patients), above Rochdale (23.5%), NHS Greater Manchester ICB (21.8%) and England (19.6%), reaching 29.4% at The Kingsway Practice and 28.1% at Dr A Hamid. Older adults aged 65+ represent 13.2% (6,566 patients), below Rochdale (14.7%), the ICB (14.9%) and England (17.9%). Roma residents comprise 0.1% (Rochdale 0.1%, the ICB 0.1%, England 0.2%) and Gypsy or Irish Traveller residents 0.1% (0.1% across comparators). Projected list growth to 2030 is 3.3% (Rochdale 1.4%, ICB 1.6%, England 2.3%); projection methodology is unverified.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Rochdale (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Rochdale LA) | 2,300 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.4% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 52.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Rochdale LA) | 1,088 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Rochdale LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 61.6% at PCN level and spans 73.0 pp across practices
Canalside PCN has 61.6% of registered patients in the Core20 cohort, with an average IMD decile of 2.5, compared with Rochdale (LAD) (48.0%; 3.6), NHS Greater Manchester ICB (40.7%; 4.5), and England (21.0%; 5.5). Weighted practice share is 63.0%, showing a 1.36 pp reconciliation difference against the PCN figure. Across practices, Core20 concentration spans 73.0 pp, from 27.0% at Castleton Health Centre to 100.0% at Dr A Hamid, while absolute workload is highest at Wellfield Health Centre with an estimated 9,789 Core20 patients.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
668
SMI register
1.36% recorded prevalence
391
Learning disability register
0.80% recorded prevalence
30
Care homes, 863 beds
In the PCN catchment
9.7%
Provide unpaid care
Rochdale (LAD), Census 2021
Recorded severe mental illness prevalence is 1.4% (668 patients) and learning disability is 0.8% (391 patients), above Rochdale (1.2% and 0.7%), NHS Greater Manchester ICB (1.1% and 0.6%), and England (1.0% and 0.6%). The PCN catchment contains 30 care homes with 863 beds, although resident registrations and occupancy are unconfirmed.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.4% (England 1.0%). Annual blood pressure checks reached 84.8% (England 83.4%), rising 8.9 pp over 2023 to 2025 (England +4.4 pp), while BMI checks trail at 80.8% (England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,109
Hypertension register
+2.91%
Register growth, 3 yrs
Rochdale (LAD) +6.17% · England +5.60%
−0.74pp
BP control, under 80
≤140/90 · +0.56pp aged 80+
+972
More patients by 2030
Forecast 8,081 (15.35%)
Hypertension case-finding and control
Hypertension prevalence is 14.5%, below Rochdale (15.6%) and England (15.2%) but above NHS Greater Manchester Integrated Care Board (14.4%), with an unadjusted register gap of +456 to +650 patients. Recorded prevalence is 9.0% at The Kingsway Practice and 18.7% at Castleton Health Centre. Patients treated to target stand at 70.0% (England 70.3%), falling 1.2% over 2023 to 2025 (England +3.6%). Blood pressure control for patients under 80 is 68.0%, falling 1.1% over 2023 to 2025 (England +3.2%). Prioritising systematic recall and treatment titration could support blood pressure control across practices with lower recorded prevalence.
Lipids and statins
Patients with QRISK ≥ 20% receiving lipid-lowering therapy stand at 70.7%, above England (63.6%) and NHS Greater Manchester Integrated Care Board (67.0%). Statin treatment for diabetes primary prevention reaches 77.3% (England 73.2%). Maintaining high lipid coverage supports ongoing primary prevention of cardiovascular events.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 82,117 | £1.70 | £1.94 | £1.86 | £139,599 |
| Cardiovascular (all), 2025 | 102,044 | £3.46 | £3.15 | £3.33 | £353,072 |
In 2026, the PCN prescribed 82,117 items of lipid-regulating drugs at £1.70 per item, below England (£1.86), Rochdale (£2.08) and NHS Greater Manchester Integrated Care Board (£1.94), spending £13,139 less than at England's unit cost and £19,708 less than at ICB unit cost. Prescribing unit costs remain lower than system and national benchmarks across captured volume.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+0.20%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.09%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.9% (1,413 patients), growing 19.6% over 2023 to 2025 (England +2.6%). Annual COPD reviews fell 4.0% over 2023 to 2025 (England +2.8%) to 74.2% (England 76.4%, Rochdale 77.2%). Asthma prevalence is 7.5% (3,379 patients); reviews stand at 61.5% (England 65.7%), rising 0.2% over 2023 to 2025 (England +4.4%), leaving about 1,300 patients unreviewed. Asthma prescribing for ages 5–19 is 1,905 items per 1,000 (England 1,488).
Cancer register and children's immunisation
Cancer prevalence is 3.0% (1,464 patients), rising 2.9% over 2023 to 2025 (England +9.0%). In Q1 2025/26 childhood immunisation across 159 children aged five, 4-in-1 booster coverage is 84.3% (below the 95.0% target by 10.7 pp), while MMR dose 2 is 85.5% (below target by 9.5 pp), trailing dose 1 at 91.2% by 5.7 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of staged cancers across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 known-stage cases), 19.4 pp below the 75.0% national ambition for 2028 (England 55.3%). Staged cancers formed 70.8% of all 16,492 registrations. Reaching 75.0% requires about 2,270 extra early-stage diagnoses annually across the ICB. PCN cancer register growth over 2023 to 2025 was +2.9% (England +9.0%, Rochdale (LAD) +9.3%), with practice changes of -6.0% at Kirkholt Medical Practice, -1.1% at Middleton Health Centre, and +0.6% at Wellfield Health Centre. Slower register growth could reflect under-detection, though crude prevalence is not age-adjusted and requires local verification.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Northern Care Alliance NHS Foundation Trust achieved 78.6% against the 85.0% 62-day cancer referral to treatment standard, 6.4 pp below standard but above England (71.2%), NHS Greater Manchester Integrated Care Board (75.7%), Manchester University NHS Foundation Trust (72.8%), and Tameside and Glossop Integrated Care NHS Foundation Trust (76.8%). On the 28-day faster diagnosis standard, Northern Care Alliance achieved 75.2%, meeting the 75.0% standard but trailing the ICB (79.5%) and England (79.3%). These provider wait figures reflect acute secondary care performance across the wider system rather than PCN delivery.
| Pathways within standard (%) | Northern Care Alliance | Tameside and Glossop Integrated Care | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.20 | 82.48 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 94.54 | 96.25 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 78.65 | 76.77 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Northern Care Alliance | Tameside and Glossop Integrated Care | Manchester | England |
|---|---|---|---|---|
| MRI | 5.09 | 0.00 | 11.68 | 21.40 |
| CT | 4.10 | 0.18 | 14.66 | 9.92 |
| Echocardiography | 31.48 | 0.00 | 4.91 | 28.48 |
| Colonoscopy | 40.04 | 1.51 | 4.51 | 30.83 |
| Gastroscopy | 36.48 | 5.45 | 29.35 | 29.02 |
| All 15 DM01 tests | 15.71 | 0.80 | 8.98 | 23.14 |
| Community services activity | Rochdale residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 60,250 | 573,310 |
| Referrals | 9,455 | 94,470 |
| Patients with a contact | 19,345 | 183,535 |
Community services (residents of Rochdale), Jun 2026 (provisional). In June 2026 (provisional), adults aged 65+ accounted for 40.9% of community service contacts among Rochdale borough residents (24,650 of 60,250 contacts). These borough-level community contacts capture wider local authority activity rather than PCN-level delivery.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF vaccination and immunisation achievement spanned an 83.1 pp range, from 16.9% at Wellfield Health Centre to 100.0% at The Hive Health Centre (England 55.2%). Overall QOF achievement ranged from 88.9% at Wellfield Health Centre to 100.0% at The Hive Health Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Kingsway | 94 | 81.5 | 79.5% | 76.1% | 91.7% |
| Hive | 99 | 48.2 | 79.0% | 72.4% | 88.9% |
| Kirkholt Medical | 97 | 83.2 | 79.7% | 71.7% | 86.0% |
| Middleton | 94 | 60.4 | 59.1% | 77.7% | 81.2% |
| Castleton | 87 | 27.0 | 67.8% | 69.2% | 79.9% |
| Wellfield | 95 | 71.3 | 63.0% | 85.6% | 76.7% |
| Dr A Hamid | 81 | 100.0 | 59.8% | 68.3% | 62.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Seventeen of 25 tracked QOF measures trailed England's three-year change
Across 25 tracked QOF measures, 17 trailed England's three-year change from 2023 to 2025. Trailing measures included learning disability prevalence, which fell 17.9% (England +5.4%), COPD reviews, which fell 4.0% (England +2.8%), and non-frail diabetes HbA1c control, which fell 0.8% (England +4.4%). Conversely, severe mental illness physical checks outpaced national trends: annual blood pressure checks rose 8.9 pp (England +4.4 pp) and alcohol recording rose 9.3 pp (England +5.4 pp). Slower progress across routine chronic care could reflect delivery pressures to explore locally.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
COPD reviews
Cancer register
Diabetes HbA1c control
Hypertension treated to target
BP check (SMI)
Alcohol record (psychosis)
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Rochdale (LAD) | Asset | PCN | Rochdale (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 30 (863 beds) | n/a | Schools (catchment) | 89 | n/a |
| Children's centres | 9 | 17 | Places of worship | 50 | 116 |
| Libraries | 3 | 12 | Primary schools (LA maintained) | 14 | 38 |
| Primary academies | 10 | 26 | Special schools | 2 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review recall
Asthma reviews are 61.5% on a register of 3,379 (England 65.7%, Rochdale (LAD) 66.2%), leaving 1,302 (about 1,300) patients unreviewed. For discussion: the PCN could run structured asthma recall using a single template and flexible after-school or holiday slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension case-finding and BP control
Hypertension prevalence is 14.5% (7,109 register; 49,671 list) versus England 15.2% and Rochdale (LAD) 15.6% (+456 to +650 unadjusted gap); under-80 BP control fell 1.1%. For discussion: practices could search for uncoded repeat raised readings and run pharmacist-led titration recall for patients above target. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Pre-school MMR and booster recall
In Q1 2025/26 across 159 age-five children, MMR dose 2 is 85.5% (5.7 pp below dose 1 at 91.2%; 9.5 pp below 95.0%) and 4-in-1 booster is 84.3% (10.7 pp below 95.0%). Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric service capacity review (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Two-track Core20 resource allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check audit (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure review audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register and referral audit (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Option 1 · Asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension case-finding and BP control (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Pre-school MMR and booster recall (p12) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
